- Home
- RCKT vs DSM Comparison
RCKT vs DSM Comparison
Compare RCKT & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCKT | DSM |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.3M | 256.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCKT | DSM |
|---|---|---|
| Price | $2.39 | $5.66 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $8.58 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 196.4K |
| Earning Date | 11-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | ★ 26.37 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $915.60 | N/A |
| P/E Ratio | $3.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $5.07 |
| 52 Week High | $5.45 | $6.30 |
Technical Indicators
Market Signals| Indicator | RCKT | DSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 67.95 |
| Support Level | $2.17 | N/A |
| Resistance Level | $2.73 | $6.21 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 64.00 | 97.52 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.